L Kristin Newby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5456118/publications.pdf Version: 2024-02-01

		66343	18647
135	19,610	42	119
papers	citations	h-index	g-index
137	137	137	22482
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
2	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, e78-e140.	2.8	2,612
3	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
4	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
5	Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. Circulation, 2011, 123, 1243-1262.	1.6	1,576
6	Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 1912.	7.4	588
7	Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2176-2190.	27.0	459
8	Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. Circulation, 2006, 113, 203-212.	1.6	453
9	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	2.8	403
10	Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events. Circulation: Cardiovascular Genetics, 2010, 3, 207-214.	5.1	390
11	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. Journal of the American College of Cardiology, 2012, 60, 2427-2463.	2.8	352
12	Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 135-142.	2.2	345
13	Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. American Heart Journal, 2012, 163, 844-850.e1.	2.7	271
14	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
15	Strategies for Improving Survival After In-Hospital Cardiac Arrest in the United States: 2013 Consensus Recommendations. Circulation, 2013, 127, 1538-1563.	1.6	258
16	Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. Circulation, 2019, 140, 1661-1678.	1.6	207
17	Benefit of Glycoprotein Ilb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status. Circulation, 2001, 103, 2891-2896.	1.6	206
18	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 547-551.	3.2	188

#	Article	IF	CITATIONS
19	Prognostic significance of elevated troponin i after percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 39, 1738-1744.	2.8	170
20	Does This Patient With Chest Pain Have Acute Coronary Syndrome?. JAMA - Journal of the American Medical Association, 2015, 314, 1955.	7.4	170
21	Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2002, 287, 3087.	7.4	136
22	Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial Infarction. New England Journal of Medicine, 2000, 342, 749-755.	27.0	127
23	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, The, 2014, 384, 1187-1195.	13.7	123
24	Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography. American Heart Journal, 2009, 157, 716-723.	2.7	121
25	Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. Journal of the American College of Cardiology, 1996, 27, 625-632.	2.8	117
26	Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis, 2014, 232, 191-196.	0.8	109
27	High‣ensitivity Troponin Assays: Evidence, Indications, and Reasonable Use. Journal of the American Heart Association, 2014, 3, e000403.	3.7	108
28	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. Journal of the American College of Cardiology, 2019, 73, 1059-1077.	2.8	103
29	Clopidogrel use and bleeding after coronary artery bypass graft surgery. American Heart Journal, 2008, 156, 886-892.	2.7	97
30	The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY) Tj ETG front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale. American Heart Journal, 2005, 149, 994-1002.	Qq0 0 0 rg 2.7	BT /Overlock 85
31	The Genesis, Maturation, and Future ofÂCritical Care Cardiology. Journal of the American College of Cardiology, 2016, 68, 67-79.	2.8	85
32	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
33	Troponin: an important prognostic marker and risk-stratification tool in non–ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S31-S36.	2.8	69
34	Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 47, 312-318.	2.8	67
35	Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome. Clinical Cardiology, 2009, 32, E22-8.	1.8	66
36	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. Journal of the American College of Cardiology, 2013, 62, 1267-1276.	2.8	65

#	Article	IF	CITATIONS
37	A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience. Journal of Cardiovascular Translational Research, 2015, 8, 449-457.	2.4	64
38	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Circulation: Heart Failure, 2019, 12, e006635.	3.9	58
39	Physical Performance Across the Adult Life Span: Correlates With Age and Physical Activity. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw120.	3.6	55
40	Outcomes of Women Compared With Men After Non–ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.	2.8	54
41	Heart Failure Complicating Non–ST-Segment Elevation Acute Coronary Syndrome. JACC: Heart Failure, 2013, 1, 223-229.	4.1	48
42	Metabolic profiles predict adverse events after coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 873-878.	0.8	45
43	Failure to Launch. JACC Basic To Translational Science, 2017, 2, 484-497.	4.1	44
44	Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1085-1094.	1.5	40
45	The Project Baseline Health Study: a step towards a broader mission to map human health. Npj Digital Medicine, 2020, 3, 84.	10.9	38
46	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e003864.	2.2	36
47	A Proposal for Modest Revision of the Definition of Type 1 and Type 2 Myocardial Infarction. Circulation, 2019, 140, 1773-1775.	1.6	35
48	Inflammation as a Treatment Target after Acute Myocardial Infarction. New England Journal of Medicine, 2019, 381, 2562-2563.	27.0	34
49	Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. American Heart Journal, 2010, 160, 371-379.e2.	2.7	33
50	Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity. American Heart Journal, 2011, 162, 64-73.	2.7	33
51	Do stable non–ST-segment elevation acute coronary syndromes require admission to coronary care units?. American Heart Journal, 2016, 175, 184-192.	2.7	31
52	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non–ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 36.	6.1	31
53	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 357-367.	2.2	30
54	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28

#	Article	IF	CITATIONS
55	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	2.7	26
56	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‣egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	26
57	Implementation of a Regional Network for STâ€Segment–Elevation Myocardial Infarction (STEMI) Care and 30â€Day Mortality in a Low―to Middleâ€Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). Journal of the American Heart Association, 2018, 7, .	3.7	26
58	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 856-864.	2.9	25
59	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. Circulation, 2021, 144, 773-787.	1.6	25
60	The Chest-Pain Unit — Ready for Prime Time?. New England Journal of Medicine, 1998, 339, 1930-1932.	27.0	24
61	The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. American Heart Journal, 2012, 164, 646-653.e3.	2.7	24
62	Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. PLoS ONE, 2015, 10, e0132259.	2.5	23
63	Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	3.7	23
64	Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041.	2.2	23
65	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. European Heart Journal, 2013, 34, 894-902.	2.2	21
66	Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practicesâ"¢ systematic review. Clinical Biochemistry, 2015, 48, 204-212.	1.9	20
67	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. Journal of the American Heart Association, 2015, 4, e001573.	3.7	20
68	The high cost of critical care unit over-utilization for patients with NSTE ACS. American Heart Journal, 2018, 202, 84-88.	2.7	19
69	A comparison of neuropsychological performance between US and Russia: Preparing for a global clinical trial. , 2014, 10, 760-768.e1.		17
70	Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events. Circulation: Cardiovascular Genetics, 2015, 8, 168-177.	5.1	17
71	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials. Circulation, 2016, 133, 1560-1573.	1.6	17
72	Age-Related Adverse Inflammatory and Metabolic Changes Begin Early in Adulthood. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 283-289.	3.6	15

#	Article	IF	CITATIONS
73	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 389-397.	2.4	14
74	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with typeÂ2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIMEâ€V study). Journal of Diabetes Investigation, 2021, 12, 200-206.	2.4	14
75	Acute coronary syndromes in the elderly. Journal of Cardiovascular Medicine, 2011, 12, 220-222.	1.5	13
76	Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis, 2016, 42, 376-385.	2.1	13
77	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. American Heart Journal, 2020, 225, 3-9.	2.7	12
78	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction. American Heart Journal, 2016, 171, 25-32.	2.7	11
79	End-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 190-197.	1.0	11
80	Myocardial Infarction Rule-out in the Emergency Department: Are High-Sensitivity Troponins the Answer?. Archives of Internal Medicine, 2012, 172, 1218.	3.8	10
81	Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology, 2013, 167, 548-554.	1.7	10
82	Association of standard clinical and laboratory variables with red blood cell distribution width. American Heart Journal, 2016, 174, 22-28.	2.7	10
83	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. American Heart Journal, 2019, 211, 54-59.	2.7	9
84	Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease. Disease Markers, 2009, 26, 265-271.	1.3	8
85	Relationship Between Peak Troponin Values and Longâ€Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	8
86	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. American Journal of Medicine, 2017, 130, 1170-1176.	1.5	8
87	SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Current Atherosclerosis Reports, 2022, 24, 627-634.	4.8	8
88	Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. Drug Design, Development and Therapy, 2015, 9, 4279.	4.3	7
89	Systematic review and directors survey of quality indicators for the cardiovascular intensive care unit. International Journal of Cardiology, 2018, 260, 219-225.	1.7	7
90	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	2.7	7

#	Article	IF	CITATIONS
91	Myocardial Ischemia on Exercise Stress Echocardiography Testing Is Not Associated with Changes in Troponin T Concentrations. journal of applied laboratory medicine, The, 2017, 1, 532-543.	1.3	7
92	Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 1996, 3, 107-115.	2.1	6
93	Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. Journal of Neuroimmunology, 2021, 354, 577541.	2.3	6
94	Improving population representation through geographic health information systems: mapping the MURDOCK study. American Journal of Translational Research (discontinued), 2014, 6, 402-12.	0.0	6
95	Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?. European Heart Journal, 2003, 24, 1613-1615.	2.2	5
96	Understanding Population Cardiovascular Health. Circulation, 2015, 132, 1303-1304.	1.6	5
97	Intravenous Beta-Blockers for Cardioprotection in STEMI. Journal of the American College of Cardiology, 2016, 67, 2716-2718.	2.8	5
98	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. International Journal of Cardiology, 2016, 203, 708-713.	1.7	5
99	Provocative biomarker stress test: stress-delta N-terminal pro-B type natriuretic peptide. Open Heart, 2018, 5, e000847.	2.3	5
100	The Impact of Multiple Dimensions of Socioeconomic Status on Physical Functioning Across the Life Course. Gerontology and Geriatric Medicine, 2018, 4, 233372141879402.	1.5	5
101	Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	2.2	5
102	Troponin testing—risk stratification to stratified medicine. Nature Reviews Cardiology, 2015, 12, 625-626.	13.7	4
103	Implications of High-Sensitivity TroponinÂTesting. Journal of the American College of Cardiology, 2018, 71, 2625-2627.	2.8	4
104	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non–ST-Segment–Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	2.2	4
105	Back to the Future. Circulation, 2015, 131, 1234-1235.	1.6	3
106	Discharge timing and outcomes after uncomplicated non–ST-segment elevation acute myocardial infarction. American Heart Journal, 2018, 201, 103-110.	2.7	3
107	High-Sensitivity Troponin in Noncardiac Surgery. Circulation, 2018, 137, 1233-1235.	1.6	3
108	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. Brazilian Journal of Cardiovascular Surgery, 2016, 31, 106-14.	0.6	3

#	Article	IF	CITATIONS
109	A new biomarker of acute coronary ischaemia: from bench to bedside?. European Heart Journal, 2022, 43, 164-166.	2.2	3
110	Applying the Evidence in Coronary Disease Secondary Prevention. Journal of the American College of Cardiology, 2014, 63, 547-548.	2.8	2
111	Sex, Region, and Outcomes After Revascularization. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	2
112	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. American Heart Journal, 2018, 199, 150-155.	2.7	2
113	Survival in Patients with Non-Ischemic Cardiomyopathy with Preserved versus Reduced Ejection Fraction. CJC Open, 2021, 3, 1333-1340.	1.5	2
114	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a Highâ€Risk Population. Journal of the American Heart Association, 2015, 4, .	3.7	1
115	Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry. European Heart Journal, 2016, 37, 161-163.	2.2	1
116	To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question. Journal of the American Heart Association, 2017, 6, .	3.7	1
117	A "shocking―new code status. American Heart Journal, 2018, 198, 1-3.	2.7	1
118	High-Sensitivity Troponin in Acute Heart Failure Triage. Circulation: Heart Failure, 2019, 12, e006241.	3.9	1
119	Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA). Molecular Genetics and Metabolism Reports, 2020, 25, 100651.	1.1	1
120	Near Real Time EHR Data Utilization in a Clinical Study. Studies in Health Technology and Informatics, 2020, 270, 337-341.	0.3	1
121	The Role of Enzymatic Markers in the New Millennium: Point-of-Care Testing and Beyond. Journal of Thrombosis and Thrombolysis, 1998, 5, S113-S118.	2.1	0
122	Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia. Evidence-Based Medicine, 2007, 12, 136-136.	0.6	0
123	Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins. Evidence-Based Medicine, 2007, 12, 42-42.	0.6	0
124	Novel Markers in Patients with Suspected Acute Coronary Syndromes. , 0, , 75-92.		0
125	Impact of Exercise Stress Testing on Diagnostic Gene Expression in Patients With Obstructive and Nonobstructive Coronary Artery Disease. American Journal of Cardiology, 2015, 115, 1346-1350.	1.6	0
126	It Happened While You Were Sleeping. Journal of the American Heart Association, 2016, 5, .	3.7	0

#	Article	IF	CITATIONS
127	Reconciling Systems for Acute Myocardial Infarction Definition and Coding Classification. Clinical Chemistry, 2017, 63, 24-26.	3.2	0
128	In-hospital cardiac arrest: Complex clinical challenges in need of unique solutions. American Heart Journal, 2017, 193, 104-107.	2.7	0
129	Response by McCord et al to Letter Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity―Cardiac Troponin Assays to Diagnose Myocardial Infarction― Circulation, 2019, 139, 564-565.	1.6	0
130	In HF with LVEF â‰Â42.5%, sacubitril–valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. Annals of Internal Medicine, 2020, 172, JC65.	3.9	0
131	In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year. Annals of Internal Medicine, 2020, 173, JC28.	3.9	0
132	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. Critical Pathways in Cardiology, 2021, Publish Ahead of Print, 173-178.	0.5	0
133	Elevated plasma natriuretic peptide levels were associated with cardiovascular events. ACP Journal Club, 2004, 141, 50.	0.1	0
134	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	1.3	0
135	Elevated plasma natriuretic peptide levels were associated with cardiovascular events. ACP Journal Club, 2004, 141, 50.	0.1	0